Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Published inLancet, vol. 381, no. 9877, p. 1541-1550
Publication date2013
Abstract
Keywords
- Adult
- Aged
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/therapy
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
Affiliation entities
Research groups
Citation (ISO format)
GABAY, Cem et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. In: Lancet, 2013, vol. 381, n° 9877, p. 1541–1550. doi: 10.1016/S0140-6736(13)60250-0
Main files (1)
Article (Published version)
Identifiers
- PID : unige:46003
- DOI : 10.1016/S0140-6736(13)60250-0
- PMID : 23515142
Journal ISSN0140-6736